| 000 | 01844 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514164648.0 | ||
| 264 | 0 | _c20040205 | |
| 008 | 200402s 0 0 eng d | ||
| 022 | _a0014-4886 | ||
| 024 | 7 |
_a10.1016/j.expneurol.2003.09.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRavenscroft, Paula | |
| 245 | 0 | 0 |
_aRopinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. _h[electronic resource] |
| 260 |
_bExperimental neurology _cJan 2004 |
||
| 300 |
_a36-46 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 |
_aBehavior, Animal _xdrug effects |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aDopamine Agonists _xtherapeutic use |
| 650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xphysiopathology |
| 650 | 0 | 4 |
_aEnkephalins _xgenetics |
| 650 | 0 | 4 |
_aGene Expression _xdrug effects |
| 650 | 0 | 4 | _aIn Situ Hybridization |
| 650 | 0 | 4 |
_aIndoles _xtherapeutic use |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aOpioid Peptides _xgenetics |
| 650 | 0 | 4 | _aOxidopamine |
| 650 | 0 | 4 |
_aParkinsonian Disorders _xchemically induced |
| 650 | 0 | 4 |
_aProtein Precursors _xgenetics |
| 650 | 0 | 4 |
_aRNA, Messenger _xmetabolism |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aSynaptic Transmission _xdrug effects |
| 700 | 1 | _aChalon, Sylvie | |
| 700 | 1 | _aBrotchie, Jonathan M | |
| 700 | 1 | _aCrossman, Alan R | |
| 773 | 0 |
_tExperimental neurology _gvol. 185 _gno. 1 _gp. 36-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.expneurol.2003.09.001 _zAvailable from publisher's website |
| 999 |
_c14427992 _d14427992 |
||